Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Label comprehension guidance on list again

This article was originally published in The Tan Sheet

Executive Summary

The Center for Drug Evaluation and Research continues developing its guidance on label comprehension studies for nonprescription drugs. The center Feb. 5 publishes its 2009 1agenda of guidances, a list that includes a total of 42 items in 14 CDER categories. Specifically, the list includes guidances on labeling dietary supplements for women who are or could be pregnant, dosage delivery devices for liquid OTCs and drug names and dosage forms. Publication of the guidance on label comprehension studies is anticipated by drug firms because questions on the design of such studies surfaced during FDA advisory committees' reviews of Rx-to-OTC switch applications (2"The Tan Sheet" Sept. 22, 2008, p. 6). CDER long has recommended improving OTC labeling and label comprehension studies to account for the growing complexity of nonprescription drugs and their indications (3"The Tan Sheet" Dec. 4, 2006, p. 9)
Advertisement
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS102589

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel